Compare IGI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGI | ACET |
|---|---|---|
| Founded | N/A | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.4M | 77.3M |
| IPO Year | 2009 | 2017 |
| Metric | IGI | ACET |
|---|---|---|
| Price | $15.97 | $7.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 26.3K | ★ 84.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.78 | $0.46 |
| 52 Week High | $17.09 | $9.05 |
| Indicator | IGI | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 47.05 |
| Support Level | $15.78 | $7.50 |
| Resistance Level | $16.57 | $8.68 |
| Average True Range (ATR) | 0.15 | 0.53 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 16.97 | 24.22 |
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).